1469 related articles for article (PubMed ID: 33712270)
21. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study.
Lim JH; Cho JH; Jeon Y; Kim JH; Lee GY; Jeon S; Noh HW; Lee YH; Lee J; Chang HH; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Kim SW
Sci Rep; 2020 Nov; 10(1):20250. PubMed ID: 33219294
[TBL] [Abstract][Full Text] [Related]
22. Therapy with RAS inhibitors during the COVID-19 pandemic.
Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C
J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584
[TBL] [Abstract][Full Text] [Related]
23. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
[TBL] [Abstract][Full Text] [Related]
24. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
25. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA
Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565
[TBL] [Abstract][Full Text] [Related]
26. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
Mancia G; Rea F; Ludergnani M; Apolone G; Corrao G
N Engl J Med; 2020 Jun; 382(25):2431-2440. PubMed ID: 32356627
[TBL] [Abstract][Full Text] [Related]
27. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ;
Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123
[TBL] [Abstract][Full Text] [Related]
28. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
[TBL] [Abstract][Full Text] [Related]
29. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
Kai H; Kai M
Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
[TBL] [Abstract][Full Text] [Related]
31. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
[TBL] [Abstract][Full Text] [Related]
32. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
Xie Q; Tang S; Li Y
Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
[TBL] [Abstract][Full Text] [Related]
33. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
34. Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19.
Rocheleau GLY; Lee T; Mohammed Y; Goodlett D; Burns K; Cheng MP; Tran K; Sweet D; Marshall J; Slutsky AS; Murthy S; Singer J; Patrick DM; Du B; Peng Z; Lee TC; Boyd JH; Walley KR; Lamontagne F; Fowler R; Winston BW; Haljan G; Vinh DC; McGeer A; Maslove D; Patrigeon SP; Mann P; Donohoe K; Hernandez G; Russell JA;
Crit Care Med; 2022 Sep; 50(9):1306-1317. PubMed ID: 35607951
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-Analysis.
Kashour T; Bin Abdulhak AA; Tlayjeh H; Hassett LC; Noman A; Mohsen A; Al-Mallah MH; Tleyjeh IM
Am J Ther; 2023 Jul-Aug 01; 30(4):e336-e346. PubMed ID: 33201001
[TBL] [Abstract][Full Text] [Related]
36. Influence of renin-angiotensin-aldosterone system inhibitors on plasma levels of angiotensin-converting enzyme 2.
Zimmermann T; Walter JE; Lopez-Ayala P; Strebel I; Amrein M; Koechlin M; Honegger U; Mueller C;
ESC Heart Fail; 2021 Apr; 8(2):1717-1721. PubMed ID: 34596976
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
Lebek S; Tafelmeier M; Messmann R; Provaznik Z; Schmid C; Maier LS; Birner C; Arzt M; Wagner S
Eur J Heart Fail; 2020 Dec; 22(12):2248-2257. PubMed ID: 33017071
[TBL] [Abstract][Full Text] [Related]
38. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
Rizk JG; Wenziger C; Tran D; Hashemi L; Moradi H; Streja E; Ahluwalia A
Drugs; 2022 Jan; 82(1):43-54. PubMed ID: 34914085
[TBL] [Abstract][Full Text] [Related]
40. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Grover A; Oberoi M
Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):148-157. PubMed ID: 32542337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]